Abstract
Medtronic, headquartered in Minneapolis, Minnesota, USA, is a major medical
technology company, specialised in implantable and interventional therapies.
Its principal products are used in bradycardia, tachyarrhythmia, heart
failure, atrial fibrillation, coronary and peripheral vascular disease, heart
valve replacement, cardiac support and surgery, spinal disorders, surgical
navigation, malignant and non-malignant pain, movement disorders, diabetes,
gastroenterology, urology, neurosurgery and ear, nose and throat (ENT) surgery.
Medtronic also previously offered gastroenterology diagnostic and
neurodiagnostic products but sold these businesses in 2007 to Alpine Biomed.
The neurodiagnostic products included the Keypoint electromyography and evoked
potentials systems, and the CLAVIS hand-held EMG/Stimulation-guided injection
device. The gastroenterology diagnostic products included the Digitrapper 400
pH recorder and Polygraf ID multi-parametric recorder for pH and manometry. In
addition, in November 2007, Medtronic also sold its Magellan Platelet Business
to Arteriocyte Medical Systems.
The company has recently significantly added to its spinal product portfolio
through the November 2007 acquisition of Kyphon for US$4.2 billion, including
the payment of debt. Kyphon' s focus is on devices designed to restore and
preserve spinal function and diagnose the source of lower back pain using
minimally-invasive technologies. Its products are used for KyphX balloon
kyphoplasty for treating vertebral compression fractures caused by
osteoporosis or cancer, in the Functional Anaesthetic Discography procedure
for diagnosing the source of lower back pain and in the Interspinous Process
Decompression procedure for treating the symptoms of lumbar spinal stenosis.
Kyphon achieved sales of US$407.8 million for the year ended 31st December
2006, representing an increase of 33% over 2005. In the nine months ended 30th
September 2007, its sales increased by 41% over the same period in 2006 to
US$417.4 million.
Medtronic' s products are sold in 120 countries worldwide. The company' s
largest geographic market is the US, which accounted for 64% of the company' s
total revenue in fiscal 2007, while sales from Europe represented 23% of
revenue, sales from the Asia-Pacific region 10% and other international
markets 3%.
This company report provides
Executive Summary
An overview of the company, including operating activities, at a glance key
events and strategic focus.
Product Portfolio and R&D
The product section of the report focuses on the key aspects of the company' s
portfolio and technology, covering core products, key brands, new products and
analysis of the competition. Sales data, market size and future potential is
included where available.
International Activities
The company' s business activities by geographic region and country.
Appendices
- Financial Indicators
- Key Corporate Events
- Mergers & Acquisitions
- Joint Ventures
- Minority Investments
- Divestitures
- Agreements
- Litigation
View Cart
